Business Wire

The SMC Group and EMCVPA Partner to Boost Jamaica’s Creative Industries

Share

Jamaica’s creative sector has received a major boost through a partnership between global entertainment marketing agency, The SMC Group, and The Edna Manley College of the Visual and Performing Arts (EMCVPA). This arrangement aims to foster the development of Jamaican talent and the island’s Creative Industries.

The venture will begin with an investment into the development of a music production studio to support local song writers, producers, and artistes. SMC also intends to recruit EMCVPA students for apprenticeships and job placements. This ground-breaking initiative will enhance the music and audio production, animation, as well as dance specialisations at the College.

The partnership is the latest positive development in the island’s creative industries which have seen considerable growth in recent years.

In the film industry, more than 4000 film-related jobs have been created in the last three years while approximately 150 foreign productions are facilitated per year​. Over 3 billion JMD in film production expenditure was contributed to GDP in the last two years,​ and approximately 65-70 percent of crews hired on most international film productions in Jamaica are local.

The country also has a growing animation industry with 15 local studios having participated in government-led programmes to increase their profitability and sustainability.

CEO of The SMC Group, Maurice Hamilton, revealed that the collaboration between the group and EMCVPA will add to the progress that has already been made in the creative industries by expanding investment into the areas of talent and content in the music and audio-visual sectors.

This is the first step of an exciting initiative to establish Jamaica and then the wider Caribbean region as a creative hub that will develop creative and business professionals as well as content,” the CEO remarked. “And for SMC, it creates a solid, efficient pipeline of creative talent to service our global clients.”

The CEO also disclosed that SMC intends to build a centre of excellence in Jamaica and will be engaging in additional investments and local partnerships.

We want to ensure that our commitment to Jamaican talent is substantive,” he insisted. “Through greater education, funding, and through our network within the global marketplace we can provide a platform from which Jamaican talent can flourish internationally.”

The island has seen several ventures over the years led by the private sector, public sector or both, which seek to advance the creative industry. Programmes such as the Business of Sustainability for Studios (BOSS) programme, JAFTA Propella film development programme, and the Film Lab initiative help entrepreneurs grow their animation and film production studios, and increase content development.

In the spirit of these collaborations between industry stakeholders, Diane Edwards, President of Jamaica’s investment and export promotions agency, JAMPRO, welcomed the cooperation between SMC and EMCVPA.

At JAMPRO, we believe that partnership is essential to building local industries and to creating valuable opportunities for Jamaica’s people, so we are pleased to see this agreement between SMC and Edna Manley College,” she said.

EMCVPA’s Vice Principal of Administration and Resource Development, Ms. Kerry Ann Henry, shared her enthusiasm for the partnership and explained that its objectives were in keeping with the college’s mission. She stated, “This is a partnership that will not just strengthen our respective organizations, it will be of enormous benefit to the country in fields related to the visual and performing arts.”

About The SMC Group

The SMC Group operates in 17 markets across the globe and has worked on campaigns for brands like The Coca-Cola Company, Net-A-Porter, Unilever, Diageo, Cartier and a host of globally recognizable names. Their projects have also involved celebrities like Jamaican Olympian Usain Bolt, Korean pop band BTS, Colombian superstar Maluma and American celebrities such as Kevin Hart, Jason Derulo and Kanye West.

ABOUT JAMPRO

The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

For more information on JAMPRO, please visit https://dobusinessjamaica.com/.

Follow us on:
Twitter
Facebook
Instagram
LinkedIn

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye